• Vaccine Name: REV DNA vaccine VP22/gag and VP22/env
• Target Pathogen: Reticuloendotheliosis Virus
• Target Disease: Tumors, wasting syndrome
• Vaccine Ontology ID: VO_0004588
• Type: DNA vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Prairie chickens
• env gene engineering:
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click Here.
• gag gene engineering:
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click Here.
• VP22 gene engineering:
  • Type: DNA vaccine construction
  • Description:
  • Detailed Gene Information: Click Here.
• DNA vaccine plasmid:
  • DNA vaccine plasmid name:
  • DNA vaccine plasmid VO ID: VO_0000158
• Immunization Route: Intramuscular injection (i.m.)

Chicken Response

• Vaccination Protocol: Four birds (two males, two females) were vaccinated four times with a combination of 500 μg of VP22/gag and 250 μg of VP22/env plasmids expressing the fusion proteins (Drechsler et al., 2013).
• Vaccine Immune Response Type: VO_0003057
• Efficacy: The DNA vaccine containing REV proteins env and gag protected against infection early after birds were repeatedly inoculated with large doses of vaccine (500 μg) as evidenced by the lack of proviral DNA in lymphocytes of the vaccinated birds at 4 wk postchallenge. In contrast, nested PCR 4 wk postinfection showed REV proviral DNA in several of the PBS and vector mock-vaccinated control birds. However, 8 wk postinfection, two out of three vaccinated birds tested positive for REV, and all birds were positive 12 wk postinfection, showing that the vaccine delayed, thus inhibited, the onset of viral replication (Drechsler et al., 2013).